Targeted Therapy Cancer Brands - High growth market will see eight new blockbusters by 2017

Targeted therapies are the top selling class of cancer drug, reaching sales of nearly $15 billion in the seven major pharmaceutical markets in 2007. The high growth of this therapy class makes it attractive to drug developers, resulting in 10 new entrants to the market since 2005. More drugs are likely to gain approval in the near future, contributing to a rapidly changing competitive landscape.

The targeted therapy cancer brands market is rapidly expanding and is forecast to maintain a high growth rate over the forecast period. The market will reach a value of over $42 billion by 2017 in the seven major pharmaceutical markets, growing at a CAGR of 11%.

Approvals in new tumor types with high unmet need, use in earlier treatment settings and growing physician familiarity are among the factors likely to drive sales of the best performing targeted therapy brands. However, pharmacoeconomic pressures and the launch of generic and pipeline competitors will dampen the growth of certain brands.

Monoclonal antibody targeted therapy cancer brands achieved higher sales than small molecule agents in 2007 and will remain the leading class over the forecast period. This is driven by the considerable success of the monoclonal antibody brands Avastin, Herceptin and Rituxan.

Read more...

• Cytotoxic Therapy Cancer Brands (09/10/2008)
• Cancer Overview (07/10/2008)
• Top 20 Therapy Cancer Brands (07/10/2008)

• Novel Therapeutic Approaches in Cardiovascular Medicine (09/10/2008)
• Diagnostics in Neurology (09/10/2008)
• Optimizing Brand Lifecycle Management (09/10/2008)

• Antihypertensives (07/10/2008)
• Asthma/COPD (07/10/2008)
• Antihormonal Therapy Cancer Brands (06/10/2008)
• Insomnia (06/10/2008)
• Commercial Insight: HIV (06/10/2008)
• Big Pharma M&A Analysis to 2012 (06/10/2008)
• Online marketing opportunities (13/06/2008)
• Drug Repositioning Strategies (10/06/2008)
• Osteoarthritis (10/06/2008)

---